Skip to Content

'
Scott Kopetz, MD, PhD, FACP

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Regular Member Graduate Faculty, Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, TX

Education & Training

Degree-Granting Education

2009 University of Texas, Graduate School of Biomedical Sciences, Houston, TX, PhD, Patient Oriented Biological Research/ Cancer Biology
2001 Johns Hopkins School of Medicine, Baltimore, MD, MD, Medicine
1997 Vanderbilt University, Nashville, TN, BE, Summa Cum Laude, Biomedical Engineering/ Electrical Engineering

Postgraduate Training

7/2004-6/2006 Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert Wolff
7/2001-6/2004 Residency, Internal Medicine, Duke University Medical Center, Durham, NC, Diana McNeil

Board Certifications

10/2006 Medical Oncology
10/2004 Internal Medicine

Experience/Service

Other Appointments/Responsibilities

Member, NCI Colon Task Force, Translational Sciences Representative, Bethesda, MD, 2012-present
Member, NCI Colon Task Force, Genomics Subcommittee, Bethesda, MD, 2012-present
Member, SWOG - Southwest Oncology Group, Ann Arbor, MI, 2012-present

Honors and Awards

2013-2016 Faculty Scholar Award, UT MD Anderson Cancer Center
2010-present Fellow, American College of Physicians
2010-2011 Gillson Longenbaugh Foundation Award, Gillson Longenbaugh Foundation
2006 The Del and Dennis McCarthy Endowed Fellowship for Gastrointestinal Cancer Research, The University of Texas MD Anderson Cancer Center
2004 Housestaff Leadership Award Recipient, Duke University Medical Center
2003 Professionalism Award, Duke University Medical School
1998 American Federation of Aging Research's Harvard Scholar, Johns Hopkins Medical School
1998 Harold Lamport Student Research Scholarship Recipient, Johns Hopkins Medical School
1997 Summa Cum Laude, Vanderbilt University
1993-1997 Harold Sterling Vanderbilt Scholar, Vanderbilt University

Selected Publications

Peer-Reviewed Original Research Articles

1. Mise Y, Kopetz S, Mehran RJ, Aloia TA, Conrad C, Brudvik KW, Taggart MW, Vauthey JN. Is Complete Liver Resection Without Resection of Synchronous Lung Metastases Justified? Ann Surg Oncol. e-Pub 11/2014. PMID: 25373535.
2. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, Kim SB, Kopetz S, Ledoux AA, Gopal YN, Pereira CG, Deng W, Lee JS, Nathanson KL, Aldape KD, Prieto VG, Stuart D, Davies MA. Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. Clin Cancer Res 20(21):5537-46, 11/2014. e-Pub 5/2014. PMCID: PMC4216765.
3. Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS, Jnag HJ, Park YY, Kopetz S, Kim SS, Oh SC, Lee JS. Significant Association of oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients. Clin Cancer Res. e-Pub 11/2014. PMID: 25388162.
4. San Lucas FA, Fowler J, Chang K, Kopetz S, Vilar E, Scheet P. Cancer in silico Drug Discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes. Mol Cancer Ther. e-Pub 10/2014. PMID: 25349306.
5. Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic Characteristics and Gene Expression Analyses of Non-KRAS 12/13, RAS-Mutated Metastatic Colorectal Cancer. Ann Oncol 25(10):2008-14, 10/2014. e-Pub 7/2014. PMCID: PMC4176451.
6. Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood AK, Hawk ET. Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prev Res (Phila) 7(10):973-92, 10/2014. e-Pub 7/2014. PMID: 25060262.
7. Zhou JH, Rosen D, Andreou A, Brouquet A, Abbott D, Loyer E, Gonzalez-Angulo AM, Kopetz S, Meric-Bernstam F, Kuerer H, Abdalla E, Vauthey JN, Sahin AA, Maru DM. Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Ann Diagn Pathol 18(5):266-70, 10/2014. e-Pub 7/2014. PMID: 25205085.
8. Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK. Therapeutic Silencing of KRAS using Systemically Delivered siRNAs. Mol Cancer Ther. e-Pub 10/2014. PMID: 25281617.
9. Chen T, Sun Y, Ji P, Kopetz S, Zhang W. Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene. e-Pub 10/2014. PMID: 25328138.
10. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 13(3):164-71, 9/2014. e-Pub 6/2014. PMID: 25069797.
11. Mise Y, Zimmitti G, Shindoh J, Kopetz S, Loyer EM, Andreou A, Cooper AB, Kaur H, Aloia TA, Maru DM, Vauthey JN. RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of Colorectal Liver Metastases. Ann Surg Oncol. e-Pub 9/2014. PMID: 25227306.
12. Aloia TA, Zimmitti G, Conrad C, Gottumukalla V, Kopetz S, Vauthey JN. Return to intended oncologic treatment (RIOT): A novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol 110(2):107-14, 8/2014. e-Pub 5/2014. PMID: 24846705.
13. Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman MJ. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 25(5):1032-8, 5/2014. e-Pub 2/2014. PMCID: PMC4072907.
14. Haynes AB, You YN, Hu CY, Eng C, Kopetz ES, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Chang GJ. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer 120(8):1162-70, 4/2014. e-Pub 1/2014. PMCID: PMC3981916.
15. Gong J, Xie J, Bedolla R, Rivas P, Chakravarthy D, Freeman JW, Reddick R, Kopetz S, Peterson A, Wang H, Fischer SM, Kumar AP. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer. Clin Cancer Res 20(5):1259-73, 3/2014. e-Pub 2/2014. PMCID: PMC3969421.
16. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH. Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase 1 Trial. Int J Radiat Oncol Biol Phys 88(2):301-5, 2/2014. e-Pub 12/2013. PMID: 24315563.
17. Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G, Izzo J, He N, Wei C, Baladandayuthapani V, Liang H, Kopetz S, Powis G, Guo GL. FXR Silencing in Human Colon Cancer by DNA methylation and KRAS Signaling. Am J Physiol Gastrointest Liver Physiol 306(1):G48-58, 1/2014. e-Pub 10/2013. PMCID: PMC3920083.
18. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pagès F. Towards the introduction of the Immunoscore in the classification of malignant tumors. J Pathol 232(2):199-209, 1/2014. e-Pub 10/2013. PMID: 24122236.
19. Kopetz S, Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru D, Elvin P, Gallick G. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer 14:660, 2014. e-Pub 9/2014. PMCID: PMC4167273.
20. Morris V, Kopetz S. Clinical biomarkers in colorectal cancer. Clin Adv Hematol Oncol 11(12):768-76, 12/2013. PMID: 24893280.
21. Vauthey JN, Kopetz SE . From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS. Cancer 119(23):4083-5, 12/2013. e-Pub 9/2013. PMID: 24105015.
22. Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, You YN, Das P, Krishnan S, Crane CH, Rodriguez-Bigas M, Skibber J, Ellis L, Eng C, Kopetz S, Maru DM. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer 119(24):4231-41, 12/2013. e-Pub 10/2013. PMID: 24089344.
23. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations. Mol Cancer Ther 12(12):2857-63, 12/2013. e-Pub 10/2013. PMCID: PMC4158732.
24. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, Curley SA, Aloia TA, Maru DM. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 258(4):619-26; discussion 626-7, 10/2013. PMCID: PMC3856211.
25. Jiang ZQ, Varadhachary G, Wang X, Kopetz S, Lee JE, Wang H, Shroff R, Katz M, Wolff RA, Fleming J, Overman MJ. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol 24(9):2349-53, 9/2013. e-Pub 5/2013. PMCID: PMC3841462.
26. Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafà R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia-Manero G, Patijn GA, Gotley DC, Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K, Taniguchi I, Song MA, Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K, Mori M, Sieuwerts AM, Martens JW, Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopetz S, Fodde R, Calin GA. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res 23(9):1446-61, 9/2013. e-Pub 6/2013. PMCID: PMC3759721.
27. Andreou A, Aloia TA, Brouquet A, Dickson PV, Zimmitti G, Maru DM, Kopetz S, Loyer EM, Curley SA, Abdalla EK, Vauthey JN. Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy. Ann Surg 257(6):1079-88, 6/2013. e-Pub 2/2013. PMCID: PMC3654038.
28. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with P13K inhibition or demethylating agents. Clin Cancer Res 19(3):657-667, 2/2013. e-Pub 12/2012. PMCID: PMC3563727.
29. Clary BM, Grothey A, Kopetz S, Marsh RD. Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. HPB (Oxford) 15(2):116-8, 2/2013. PMCID: PMC3719917.
30. Overman MJ, Modak J, Kopetz ES, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL. Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed? J Clin Oncol 31(1):17-22, 1/2013. e-Pub 11/2012. PMID: 23129736.
31. Morris V, Kopetz S. BRAF inhibitors in clinical oncology. F1000Prime Rep 5:11, 2013. e-Pub 4/2013. PMCID: PMC3619157.
32. Park YY, Lee SS, Lim JY, Kim SC, Kim SB, Sohn BH, Chu IS, Oh SC, Park ES, Jeong W, Kim SS, Kopetz S, Lee JS. Comparison of prognostic genomic predictors in colorectal cancer. PLoS One 8(4):e60778, 2013. e-Pub 4/2013. PMCID: PMC3634034.
33. Park YY, Lee SS, Lim JY, Kim SC, Kim SB, Sohn BH, Chu IS, Oh SC, Park ES, Jeong W, Kim SS, Kopetz S, Lee JS. Correction: Comparison of Prognostic Genomic Predictors in Colorectal Cancer. PLoS One 8(12), 2013. e-Pub 12/2013. PMCID: PMC3866352.
34. Overman MJ, Zhang J, Kopetz S, Davies M, Zhi-Qin J, Stemke-Hale K, Rümmele P, Pilarsky C, Grützmann R, Hamilton S, Hwang R, Abbruzzese JL, Varadhachary G, Broom B, Wang H. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One 8(6):e65144, 2013. e-Pub 6/2013. PMCID: PMC3679143.
35. Kopetz S. "Right drug for the right patient". Am Soc Clin Oncol Educ Book 2013:115-20, 2013. PMID: 23714474.
36. Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One 8(10):e77117, 2013. e-Pub 10/2013. PMCID: PMC3797099.
37. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases. J Clin Oncol 30(36):4566-72, 12/2012. e-Pub 11/2012. PMCID: PMC3518730.
38. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz ES, Win S, Kurzrock R. Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: the MD Anderson Cancer Center Experience. Clin Colorectal Cancer 11(4):297-303, 12/2012. e-Pub 4/2012. PMID: 22537607.
39. Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN. Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases. Ann Surg 256(4):642-50, 10/2012. e-Pub 9/2012. PMCID: PMC3856177.
40. Vauthey JN, Kopetz S, Aloia TA, Andreou A. KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary. Br J Cancer 107(8):1442-3, 10/2012. e-Pub 9/2012. PMCID: PMC3494431.
41. Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB, Kim J, Kim SC, Chu IS, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee JS. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 61(9):1291-8, 9/2012. e-Pub 10/2011. PMCID: PMC3419333.
42. Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C. Survival Benefit Associated With Surgical Oophorectomy in Patients With Colorectal Cancer Metastatic to the Ovary. Clin Colorectal Cancer 11(3):191-4, 9/2012. e-Pub 1/2012. PMID: 22280844.
43. Dai J, Gu J, Huang M, Eng C, Kopetz ES, Ellis LM, Hawk E, Wu X. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis 33(7):1327-31, 7/2012. e-Pub 4/2012. PMID: 22505654.
44. Overman MJ, Hu CY, Kopetz ES, Abbruzzese JL, Wolff RA, Chang GJ. A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease. Ann Surg Oncol 19(5):1439-45, 5/2012. e-Pub 12/2011. PMCID: PMC3342860.
45. Ferrarotto R, Machado K, Mak MP, Shah N, Takahashi TK, Costa FP, Overman MJ, Kopetz S, Hoff PM. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer 48(6):820-6, 4/2012. e-Pub 2/2012. PMID: 22330318.
46. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 72(3):779-89, 2/2012. e-Pub 12/2011. PMID: 22180495.
47. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10(1):205, 2012. e-Pub 10/2012. PMCID: PMC3554496.
48. Boonsirikamchai P, Asran MA, Maru DM, Vauthey JN, Kaur H, Kopetz ES, Loyer EM. CT Findings of Response and Recurrence, Independent of Change in Tumor Size, in Colorectal Liver Metastasis Treated With Bevacizumab. AJR Am J Roentgenol 197(6):W1060-6, 12/2011. PMID: 22109320.
49. Angelo LS, Wu JY, Meng F, Sun M, Kopetz S, McCutcheon IE, Slopis JM, Kurzrock R. Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. Mol Cancer Ther 10(11):2094-103, 11/2011. e-Pub 9/2011. PMID: 21903608.
50. Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis. Clin Cancer Res 17(19):6130-9, 10/2011. e-Pub 9/2011. PMID: 21953501.
51. Brouquet A, Overman MJ, Kopetz ES, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer 117(19):4484-92, 10/2011. e-Pub 3/2011. PMCID: PMC3128184.
52. Ferrarotto R, Pathak P, Maru D, Agarwal A, Overman M, Hoff PM, Kopetz ES. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 10(3):178-82, 9/2011. e-Pub 4/2011. PMID: 21855039.
53. George B, Kopetz ES. Predictive and Prognostic Markers in Colorectal Cancer. (Invited). Curr Oncol Rep 13(3):206-15, 6/2011. e-Pub 3/2011. PMID: 21373987.
54. Fogelman DR, Wolff RA, Kopetz ES, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL. Evidence for the Efficacy of Iniparib, a PARP-1 Inhibitor, in BRCA2-associated Pancreatic Cancer. Anticancer Res 31(4):1417-20, 4/2011. PMID: 21508395.
55. Brouquet A, Abdalla EK, Kopetz ES, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29(8):1083-90, 3/2011. e-Pub 1/2011. PMCID: PMC3068054.
56. Tran B, Kopetz ES, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. e-Pub 3/2011. PMID: 21456008.
57. Ihle NT, Powis G, Kopetz ES. PI-3-Kinase Inhibitors in Colorectal Cancer (Peer-reviewed Review). Curr Cancer Drug Targets 11(2):190-8, 2/2011. e-Pub 12/2010. PMID: 21158718.
58. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz ES, McConkey DJ, Evans DB, Gallick GE. ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma. PLoS One 6(6):e20636, 2011. e-Pub 6/2011. PMCID: PMC3113804.
59. Silberfein EJ, Kattepogu KM, Hu CY, Skibber JM, Rodriguez-Bigas MA, Feig B, Das P, Krishnan S, Crane C, Kopetz S, Eng C, Chang GJ. Long-term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer. Ann Surg Oncol 17(11):2863-9, 11/2010. e-Pub 6/2010. PMCID: PMC3071558.
60. Maru DM, Kopetz S, Boonsirikamchai P, Agarwal A, Chun YS, Wang H, Abdalla EK, Kaur H, Charnsangavej C, Vauthey JN, Loyer EM. Tumor Thickness at the Tumor-normal Interface: A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases. Am J Surg Pathol 34(9):1287-1294, 9/2010. e-Pub 8/2010. PMID: 20697255.
61. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, Curley SA, Abdalla EK, Capussotti L, Vauthey JN. Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases. Ann Surg Oncol 17(11). e-Pub 6/2010. PMID: 20567921.
62. Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, Kopetz S, Garrett C, Curley SA, Abdalla EK. Surgical Strategies for Synchronous Colorectal Liver Metastases in 156 Consecutive Patients: Classic, Combined or Reverse Strategy? J Am Coll Surg 210(6):934-41, 6/2010. PMID: 20510802.
63. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 49(4):474-9, 5/2010. PMID: 20397775.
64. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA, Kopetz S. Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury. J Clin Oncol 28(15):2549-2555, 5/2010. e-Pub 4/2010. PMID: 20406923.
65. Lieu C, Kopetz S. The SRC family of protein tyrosine kinases: A new and promising target for colorectal cancer therapy. (Peer-reviewed Review). Clin Colorectal Cancer 9(2):89-94, 4/2010. PMCID: PMC3091503.
66. Vauthey JN, Nordlinger B, Kopetz S, Poston G. Sequenced Chemotherapy and Surgery for Potentially Resectable Colorectal Liver Metastases: A Debate Over Goals of Research and an Approach While the Jury Remains Out. Ann Surg Oncol 17(8):1983-1986, 3/2010. PMID: 20232164.
67. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102(1):144-50, 1/2010. e-Pub 11/2009. PMCID: PMC2813754.
68. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. J Clin Oncol 28(3):453-9, 1/2010. e-Pub 12/2009. PMCID: PMC2815707.
69. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Charnsangavej C, Loyer EM. Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases. JAMA 302(21):2338-2344, 12/2009. PMID: 19952320.
70. Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, Kopetz S. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 8(4):225-30, 10/2009. PMID: 19822514.
71. Kopetz S, Chang G, Overman M, Eng C, Larson DW, Grothey A, Vauthey JN, Sargent D, McWilliams R. Improved Survival in Metastatic Colorectal Cancer is Associated with Sequential Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 27(22):3677-83, 8/2009. e-Pub 5/2009. PMCID: PMC2720081.
72. Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Delclos ME, Krishnan S, Crane CH, Das P.. Sacral Insufficiency Fractures After Preoperative Chemoradiation for Rectal Cancer: Incidence, Risk Factors, and Clinical Course. Int J Radiat Oncol Biol Phys 74(3):818-23, 7/2009. e-Pub 1/2009. PMID: 19147305.
73. Rossi S, Kopetz S, Davuluri R, Hamilton SR, Calin GA. MicroRNAs, ultraconserved genes and colorectal cancers. (Invited). Int J Biochem Cell Biol 42(8):1291-1297, 6/2009. e-Pub 6/2009. PMID: 19497386.
74. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 26(15S):4538, 6/2009. e-Pub 1/2009. PMID: 19164203.
75. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE.. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9):3842-9, 5/2009. e-Pub 4/2009. PMCID: PMC2709758.
76. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16(3):614-22, 3/2009. e-Pub 1/2009. PMID: 19130139.
77. Kim MP, Park SI, Kopetz S, Gallick GE.. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res 1(335):249-59, 1/2009. e-Pub 9/2008. PMID: 18815812.
78. Chang DZ, Kumar V, Ma Y, Li K, Kopetz S. Individualized Therapies in Colorectal Cancer: KRAS as a Marker for Response to EGFR-targeted Therapy (Invited Editorial). J Hematol Oncol 2(18):18, 2009. e-Pub 4/2009. PMCID: PMC2686726.
79. Fogelman DR, Kopetz S, Eng C. Emerging Drugs for Colorectal Cancer (Invited). Expert Opin Emerg Drugs 13(4):629-42, 12/2008. PMID: 19046131.
80. Blazer DG, Kish U, Maru DM, Kopetz S, Overman M, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover K, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point after Resection of Hepatic Colorectal Metastases. J Clin Oncol 59(33):5344-51, 11/2008. e-Pub 10/2008. PMID: 18936472.
81. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26(32):5254-60, 11/2008. e-Pub 10/2008. PMID: 18854565.
82. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 113(8):2038-45, 10/2008. PMID: 18759326.
83. Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26(8):794-9., 10/2008. PMID: 18798063.
84. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbrizzese JL. Phase I study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest. New Drugs 26(5), 10/2008. e-Pub 6/2008. PMID: 18528634.
85. Hoff PM, Kopetz S, Thomas MB, Langleben A, Rinaldi D, Anthony L, Wolff RA, Lassere Y, Abbruzzese JL. A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer 99(5):722-6, 9/2008. e-Pub 8/2008. PMID: 18728662.
86. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer 7(5):338-42, 9/2008. PMID: 18794067.
87. Kauffman CR, Mahvash A, Kopetz S, Wolff RA, Ensor J, Wallace MJ. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. Cancer 14(10):2283-8, 5/2008. PMID: 18344210.
88. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway. J Clin Oncol 26(12):2000-5, 4/2008. PMID: 18421052.
89. Kopetz S, Freitas D, Calabrichi A, Hoff PM. Adjuvant Chemotherapy for Stage II Colon Cancer (Peer-Reviewed Review). Oncology 22(3):260-70, 3/2008. PMID: 18494354.
90. Dhillon N, Kopetz S, Pei BL, Fabbro ED, Zhang T, Bruera E. Clinical findings of a palliative care consultation team at a comprehensive cancer center. J Palliat Med 11(2):191-7, 3/2008. PMID: 18333733.
91. Politano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz S. Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness. Clin Colorectal Cancer 1(1):55-9, 1/2008. PMID: 18279578.
92. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. J Gastrointest Surg 11(11):1498-1505, 11/2007. e-Pub 9/2007. PMID: 17849166.
93. Kopetz S, Jimenez C, Tu SM, Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. Eur Respir J 29(4):813-5, 12/2006. PMID: 17400880.
94. Kopetz S. Endothelin-1 as a Target For Therapeutic Intervention in Prostate Cancer (Invited). Invest New Drugs 20:173-82, 5/2002. PMID: 12099577.
95. Kopetz ES, TH Magnuson, MD Duncan, JS Bender, KD Lillemoe, TA Gordon, JL Cameron, JW Harmon. Complications of neglected cholelithiasis account for significant surgical mortality in the elderly. Surg Forum(52):489-91, 10/2000.
96. Kopetz S, Steele CD, Brandt J, Baker A, Kronberg M, Galik E, Steinberg M, Warren A, Lyketsos CG. Characteristics and outcomes of dementia residents in an assisted living facility. Int J Geriatr Psychiatry 15(7):586-93, 7/2000. PMID: 10918338.
97. Cheng MD, Nash TM, Kopetz ES. Retrieval of Aerosol Optical Thickness by Means of the Least-Median-Squares Robust Algorithm. Journal of Aerosol Science 30:805-17, 1/1999.
98. Walczak WJ, Xiao JM, Kopetz ES, Lease K, Grau H, Lee SP, Han MK, and Knutson JR. Golden Ruler: Very Long-Range Resonance Energy Transfer to Surface Plasmon Acceptors. Biophysical Journal, 72:367, 2/1997.

Invited Articles

1. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev 33(1):231-69, 3/2014. e-Pub 4/2014. PMCID: PMC4186918.
2. Kopetz S. Novel Targets for Systemic Therapy of Colorectal Cancer. Clin Adv Hematol Oncol 6(1):38-40, 1/2008. PMID: 18322439.
3. Kopetz S, Shah AN, Gallick GE. SRC continues aging: current and future clinical directions. Clin Cancer Res 13(24):7232-6, 12/2007. PMID: 18094400.
4. Kopetz S. Targeting Src and Epidermal Growth Factor Receptor in Colorectal Cancer: Rationale and Progress Into the Clinic. Gastrointestinal Cancer Research 1:S37-41, 7/2007.
5. Kopetz S, Hoff PM. Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in management. Oncology (Williston Park) 19(13 Suppl 6):11-7, 11/2005. PMID: 16502665.
6. Kopetz S, Kim ES. Adjuvant Chemotherapy in Non-Small Cell Lung Cancer. American Journal of Oncology Review (Pulmonary Supplement):1-4, 2/2005.

Editorials

1. Davies MA, Kopetz S. Overcoming resistance to MAPK pathway inhibitors. J Natl Cancer Inst 105(1):9-10, 1/2013. e-Pub 12/2012. PMID: 23250957.
2. Morelli MP, Kopetz S. Hurdles and complexities of codon 13 KRAS mutations. J Clin Oncol 30(29):3565-7, 10/2012. e-Pub 8/2012. PMID: 22927534.
3. Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res 18(19):5160-2, 10/2012. e-Pub 8/2012. PMID: 22912394.
4. Kopetz S, Abbruzzese J. Barriers to Integrating Gene Profiling for Stage II Colon Cancer. Clinical Cancer Research 15(24), 12/2009. PMID: 19996205.
5. Eng C, Kopetz S. Commentary: Practice Patterns and Potential Impact on Quality Measurements for a Practicing Physician. Journal of Oncology Practice 5(5):233-5, 9/2009.
6. Overman M, Kopetz S. Picking the Right Road for Metastatic Colorectal Cancer Patients. Oncology 22(13):1482-3, 11/2008. PMID: 19227576.
7. Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet 371(9617):963-5, 3/2008. PMID: 18358910.

Abstracts

1. Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Hartmann A, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10(1). e-Pub 10/2012. PMID: 23034130.
2. Kopetz S, Lemos R, Powis G. The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men. Clinical Cancer Research, 8/2012.
3. Overman MJ, Eng C, Kee BK, Fogelman DR, Fark C, Hippert R, Holter S, Issa JP, Hamilton SR, Kopetz S. A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer. J Clin Oncol 30 (#450), 2012.
4. Corcoran RB, Falchook GS, Infante JR, Hamid O, Messersmith WA, Kwak EL, Ryan DP, Kurzrock R, Brenner AA, Luan J, Sun P, Allred AJ, Little SM, Patel L, Kopetz S, Venook AP. BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212). J Clin Oncol 30 (#3528), 2012.
5. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey J, Rodriguez-Bigas MA, Curley SA, Feig BW. Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab (BV) for colorectal cancer (CRC) liver metastases. 2007 Gastrointestinal Cancers Symposium (#234), 2012.
6. Chen ZY, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong DS, Hoff PM, Tran HT, Heymach J, Overman MJ, Kopetz S. Correlation of specific cytokine profiles with high blood neutrophil-to-lymphocyte ratio and outcome in metastatic colorectal cancer. J Clin Oncol 30 (#3598), 2012.
7. Raghav KPS, Kalil K, Ferrarotto R, George B, Eng C, Garrett CR, Loyer E, Hoff PM, Charnsangavej C, Kopetz S, Overman MJ. Effect of bevacizumab on rate of oxaliplatin-induced thrombocytopenia and splenomegaly. J Clin Oncol 30 (#3544), 2012.
8. Chang GJ, Park IJ, Eng C, You YN, Kopetz S, Overman MJ, Rodriguez-Bigas MA, Skibber JM. Exploratory analysis of adjuvant chemotherapy benefits after preoperative chemoradiotherapy and radical resection for rectal cancer. J Clin Oncol 30 (#3556), 2012.
9. Park IJ, Eng C, You, YN, Kopetz S, Rodriguez-Bigas MA, Overman MJ, Skibber JM, Chang GJ. Exploratory analysis of adjuvant chemotherapy effects after preoperative chemoradiotherapy and radical resection for rectal cancer. 2012 Gastrointestinal Cancers Symposium (#557), 2012.
10. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, Maru D, Munsell MF, Clemons MV, Kopetz S, Garrett CR, Shureiqi I, Krishnan S, Delclos ME, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal adenocarcinoma: A phase I trial. J Clin Oncol 30 (#544), 2012.
11. Shah NN, Lieu CH, Ivan C, Overman MJ, Shimizu M, Morris J, Tran H, Heymach J, Calin G, Kopetz S. Prognostic effects of circulating markers of epithelial mesenchymal transition (EMT) in metastatic colorectal cancer patients. J Clin Oncol (#456), 2012.
12. Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru DM, Elvin D, Kopetz S, Gallick GE. Relationship of Src activity and prior oxaliplatin on outcomes after hepatectomy for metastatic colorectal cancer. J Clin Oncol 30 (#3561), 2012.
13. Chen Z, Overman MJ, Garrett CR, Jiang ZQ, Wolff RA, Abbruzzese JL, Eng C, Kopetz S. Systematic survey of therapeutic trials for metastatic colorectal cancer. J Clin Oncol 30 (#523), 2012.
14. Overman MJ, George B, Kalil K, Ferrarotto R, Eng C, Garrett CR, Loyer E, Hoff PM, Charnsangavej C, Kopetz S. Use of bevacizumab to reduce the rate of oxaliplatin-induced thrombocytopenia and splenomegaly. J Clin Oncol 30 (#564), 2012.
15. Mao M, Tsao L, Dayyani F, Gopal V, Nanda Y, Mills G, Bollag G, Davies M, Gallick G, Kopetz S. Resistance to BRAF inhibition in BRAF V600E colorectal cancer is associated with PI3K/AKT activation and hypermethylation. AACR 2011:LB-228, 4/2011.
16. Kopetz S, Tran HT, Cunningham D, Mookerjee B, Pike L, Jurgensmeier J, Heymach J. Association of circulating cytokine and angiogenic factors (CAFs) with outcomes to second-line FOLFOX plus bevacizumab or cediranib in metastatic colorectal cancer. J Clin Oncol 29((suppl 4; abstr 406)), 1/2011.
17. Jiang Z, Mehta TR, You YN, Chang GJ, Eng C, Overman MJ, Maru M, Hamilton SR, Kopetz S. Association of PTEN loss and local recurrence in stage II-III colon cancer. J Clin Oncol 29((suppl 4; abstr 399)), 1/2011.
18. Lieu CH, Tran HT, Fiorentino S, Jiang Z, Mao M, Overman MJ, Eng C, Ellis LM, Heymach J, Kopetz S. Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer. J Clin Oncol 29((suppl 4; abstr 401)), 1/2011.
19. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM). J Clin Oncol 29((suppl 4; abstr 507)), 1/2011.
20. George B, You Y, Viswanathan C, Wen S, Baladandayuthapani V, Overman MJ, Kee BK, Kopetz S, Eng C, Garrett CR. Survival advantage associated with palliative oophorectomy in patients with metastatic colorectal cancer (CRC) to the ovaries (mCRC-O): A single institution retrospective analysis. J Clin Oncol 29((suppl 4; abstr 539)), 1/2011.
21. Ferrarotto R, Machado KK, Mak MP, Vieira VA, Takahashi TK, Saragiotto DF, Kopetz S, Overman MJ, Hoff PM. A multicenter, multinational retrospective analysis of mitomycin C (MMC) in refractory metastatic colorectal cancer (mCRC). J Clin Oncol 29 (#3577), 2011.
22. Kopetz S, Tran HT, Cunningham D, Mookerjee B, Pike L, Jurgensmeier J, Heymach J. Association of circulating cytokine and angiogenic factors (CAFs) with outcomes to second-line FOLFOX plus bevacizumab or cediranib in metastatic colorectal cancer. J Clin Oncol 29 (#406), 2011.
23. Jiang Z, Mehta TR, You YN, Chang GJ, Eng C, Overman MJ, Maru D, Hamilton SR, Kopetz S. Association of PTEN loss and local recurrence in stage II-III colon cancer. J Clin Oncol 29 (#399), 2011.
24. George B, Estrella J, Machado L, Ferrarotto R, Hoff PM, Rashid A, Kopetz S. High-grade neuroendocrine carcinomas (HGNECs) of the colon and rectum: A single-institution retrospective analysis. J Clin Oncol 29 (#e14040), 2011.
25. Lieu CJ, Tran HT, Fiorentino S, Jiang Z, Mao M, Overman MJ, Eng C, Ellis LM, Heymach J, Kopetz S. Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer. J Clin Oncol 29 (#401), 2011.
26. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM). J Clin Oncol 29 (#507), 2011.
27. Hassabo HM, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM). J Clin Oncol 29 (#3618), 2011.
28. George B, You YN, Viswanathan C, Wen S, Baladandayuthapani V, Overman MJ, Kee BK, Kopetz S, Eng C, Garrett CR. Survival advantage associated with palliative oophorectomy in patients with metastatic colorectal cancer (CRC) to the ovaries (mCRC-O): A single institution retrospective analysis. J Clin Oncol 29 (#539), 2011.
29. Lieu CH, Tran HT, Jiang Z, Mao M, Overman MJ, Eng C, Morris J, Ellis LM, Heymach J, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. J Clin Oncol 29 (#3533), 2011.
30. Tran B, Kopetz S, Tie Jeanne, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Distinct Differences in Sites of Metastatic Disease May Contribute to Poorer Outcomes Observed in Patients with BRAF Mutant Colorectal Cancers. ASCO 2010, 6/2010.
31. Chang G, Maru D, Agarwal A,Schlette E, Wolff R, Rodriguez-Bigas M, You N, Feig B, Kopetz S, Skibber J, Eng C. Histopathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone. 12th World Congress on Gastrointestinal Cancer, 6/2010.
32. Chang G, Maru D, Agarwal A, Schlette E, Wolff R, Rodriguez-Bigas M, You N, Feig B, Kopetz S, Skibber J, Eng C. Histopathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone. Annals of Oncology, 6/2010.
33. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee R.J., Nolop KB, Bhattacharya S, Saltz L. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. ASCO 2010, 6/2010.
34. Agarwal A, Kopetz S, Boonsirikamchai P, Chun YS, Wang H, Vauthey JN, Loyer EM, Maru DM. Tumor Thickness at Tumor-Normal Interface (TNI): A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases (HCRM). United States and Canadian Academy of Pathology (USCAP), 3/2010.
35. Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z, Lieu CH, Agarwal A, Maru D, Sieber O, Desai J. Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers. J Clin Oncol 28 (#3592), 2010.
36. Lieu CH, Wolff RA, Eng C, Overman MJ,Henry L, Coulson R, Garrett CR, Abbruzzese JL, Gallick GE, Kopetz S. Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. J Clin Oncol 28(7) (#3536), 2010.
37. Boonsirikamchai P, Maru DM, Chun YS, Kaur H, Kopetz S, Loyer EM. New CT Findings of Response and Recurrence Independent of Change in Tumor Size in Colorectal Liver Metastasis Treated with Bevacizumab. presented at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Chicago, 11/2009.
38. Pozadzides K, Wang H, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Overman MJ. Immunophenotype and molecular characterization of small bowel adenocarcinoma. Gastrointestinal Cancers Symposium, 2009.
39. Kopetz S, Hoff P, Eng C, Overman MJ, Glover KY, Chang DZ, Wolff RA, Abbruzzese JL, Ellis LM, Heymach JV. Levels of angiogenic cytokines prior to disease progression in metastatic colorectal cancer patients treated with bevacizumab. Gastointestinal Cancers Symposium:292 (#292), 2009.
40. Chun YS, Kopetz S, Palavecino M, Zorzi D, Curley SA, Abdalla EK, Vauthey JN. Proposal of new staging in advanced colorectal cancer. Gastrointestinal Cancers Symposium:304, 2009.
41. Sankhala K, Takimoto C, Mita A, Xiong H, Rodon JA, Adinin R, Burns K, Toko T, Arakawa K, Kopetz S. Two Phase I, Pharmacokinetic (PK) and Pharmacodynamic (PD) Studies of TAS-109, a novel nucleoside analogue with 14 days and 7 days continuous infusion (CI) schedules. ASCO 2008, 6/2008.
42. Kopetz S, Wolff R, Eng C, Henry L, Glover K, Chang D, Overman M, Gallick G, Abbruzzese J. Phase IB study of Src inhibitation with dasatinib in combination with 5-fluorouracil, leuvocorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer. AACR Meeting Abstracts:LB-69, 4/2008.
43. Eng C, Kopetz S, Morris J, Malik Z, Stewart D, Chang H, Ohinata A, Abbruzzese J, Gallick G. Phase II study of the novel oral Src-kinase inhibitor, AZD0530, in previously treated advanced colorectal cancer patients. AACR Meeting Abstracts:LB-76, 4/2008.
44. Kopetz S, Mita MM, Sankhala KK, Moseley J, Sherman BM, Bradley CR, Tolcher AW. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. 2008 ASCO Annual Meeting (#3577), 2008.
45. Kopetz S. Phase I study of Src inhibition with dasatinib in combination with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer. 2008 ASCO Gastrointestinal Cancers Symposium, 2008.
46. Politano S, Pathak P, Hoff PM, Charnsangavej C, Overman MJ, Loyer E, Vauthey J, Wallace MJ, Wolff RA, Kopetz S. The use of 5-fluorouracil and oxaliplatin (FOLFOX) for colorectal cancer is associated with the development of splenomegaly and thrombocytopenia. 2008 ASCO Annual Meeting (#4102), 2008.
47. Kopetz S, Shah AN, Gallick GE. Src Continues Aging: Current and Future Clinical Directions. Clinical Cancer Research:7232, 12/2007.
48. Kopetz S. Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer. 2007 ASCO Annual Meeting (#4089), 2007.
49. Chang D, Zhu K, Kopetz S, Voo K, Li Y, Hwu P, Radvanyi L, Abbruzzese JL. Presence of survivin-specific cytotoxic T-lymphocytes (CTLs) in pancreatic cancer patients, and specific killing of human pancreatic carcinoma cells in vitro by survivin-specific CTLs. 2007 ASCO Annual Meeting (#3070), 2007.
50. Kopetz S, Wu J, Davies M, Parikh N, Johnson F, Gallick G, Donato N. Synergistic activity of Src and EGFR inhibitors in colon cancer. AACR Annual Meeting (#4079), 2007.
51. Kopetz S, Wu J, Davies M, Johnson F, Donato N. Synergistic effects of combination therapy with anti-EGFR and anti-Src therapy in vitro in colon cancer. ASCO Gastrointestinal Cancers Symposium (#406), 2007.
52. Kopetz S, Wu J, Johnson F, Donato N. Anti-tumor effects of combination therapy with anti-EGFR and anti-Src therapy in colorectal cancer. AACR Meeting Abstracts:B51, 9/2006.
53. Kopetz S, Dang J, Overman M, Phan L, Feig B, Patel D, Wolff RA, Eng CA, Abbruzzese JL, Hoff P. Bevacizumab toxicity and efficacy are unaffected by regimen or resection status: A single institution retrospective study. Gastrointestinal Cancers Symposium (#243), 2006.
54. Kopetz S, Eng C, Adinin R, Wolff RA, Lin E, Chang DZ, Abbruzzese JL, Hoff PM. Preliminary results from a phase II study of FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). 2006 ASCO Annual Meeting, 2006.
55. Kopetz S, Eng C, Adinin RB, Wolff RA, Lin E, Chang DZ, Abbruzzese JL, Hoff PM. Preliminary results from a phase II study of FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). 2006 World GI Congress, 2006.
56. Hoff PM, Eng C, Adinin RB, Wolff RA, Lin E, Kopetz S, Rodney A, Chang DZ, Abbruzzese JL. Preliminary results from a phase II study of FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). Gastrointestinal Cancers Symposium, 2006.
57. Dhillon N, Kopetz S, Del Fabbro E, Reddy S, Bruera E. The Establishment Of A Palliative Care Consult Team In A Comprehensive Cancer Center. 2005 ASCO Annual Meeting (#8093), 2005.

Book Chapters

1. Hong DS, Kopetz ES, George GC. Colorectal Cancer (Adenocarcinoma). In: Handbook of Targeted Cancer Therapy. Ed(s) Karp DD, Falchook GS. Wolters Kluwer Health, 2014. ISBN: 1451193262.
2. Hoff PMG, Kopetz S. Systemic Therapy for Non-operable Colorectal Cancer Metastases. In: Liver Metastases. Ed(s) Vauthey JN, Hoff PMG, Audisio RA, Poston GJ. Springer: United States of America, 51-8, 2008. ISBN: 978-1-84628-946-0.
3. Kopetz S. Targeted Therapy in Cancer. In: Targeted Therapy for Colorectal Cancer. Ed(s) Razelle Kurzrock, Maurie Markman. Humana Press: United States, 101-24, 2008. ISBN: 978-1-60327-423-4.
4. Kopetz S, Raber M, Abbruzzese J. Colorectal, Anal, and Unknown Primary Cancer (electronic web update). In: Cancer Medicine, 2006.
5. Kopetz S, Hoff P. Management Issues in Patients Presenting with Stage IV Colorectal Cancer. In: Advanced Therapy in Surgical Oncology. Ed(s) Stephen Curley, Raph Pollock, Merrick Ross, and Nancy Perrier. Decker Press, 281-91, 2006. ISBN: 978-1-55009-126-7.

Letters to the Editor

1. Vauthey JN, Zorzi D, Kopetz S, Abdalla EK, Kishi Y, Blazer DG. Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival Reply. J Clin Oncol 27(20):E20-E21, 7/2009.
2. Vauthey JN, Zorzi D, Kopetz S, Abdalla EK, Kishi Y, Blazer DG, III. Reply to Colorectal hepatic metastases: adjuvant chemotherapy and survival by D. Gallagher et al. J Clin Oncol 27(20):e20-1, 7/2009.
3. Kopetz S, Abbruzzese JL.. Hidden Biases in an Observational Study of Bevacizumab Beyond Progression. J Clin Oncol 27(10):1732-3, 4/2009. e-Pub 3/2009. PMID: 19255299.
4. Overman M, Kopetz S. First-Line Therapeutic Strategies in Metastatic Colorectal Cancer The Davies/Goldberg Article Reviewed. Oncology, New York-New York 22(13):1482-1483, 11/2008.

Manuals, Teaching Aids, Other Teaching Publications

1. Kopetz ES. Etiology and Management of Bowel Perforation in Patients with Colorectal Cancer” Gastrointestinal Malignancies: Putting Theory Into Practice at M. D. Anderson. M. D. Anderson: Houston, Texas, 2007.

Grant & Contract Support

Title: Tumor Heterogeneity and Acquired Resistance to EGFR Inhibition
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 12/2/2014 - 11/30/2019
 
Title: Southwest Early Clinical Trials Consortium
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Funda Meric-Bernstam, MD
Duration: 2/1/2014 - 1/31/2019
 
Title: Classification and mechanism of cetuximab acquired resistance in colorectal cancer
Funding Source: UT MD Anderson Cancer Center
Role: Principal Investigator
Duration: 1/1/2013 - 12/31/2014
 
Title: Integrating Genomics and epigenomics in Stage II and III Colon Cancer: Colon Cancer Integromics.
Funding Source: UT MD Anderson Cancer Center - Hogan Award
Role: Principal Investigator
Duration: 7/1/2011 - 6/30/2013
 
Title: Bevacizumab Modulation of Radiographic Response and Oxaliplatin-Associated Hepatic Toxicity
Funding Source: Roche
Role: Principal Investigator
Duration: 6/21/2011 - 4/30/2015
 
Title: PTEN-loss enriched Akt inhibition clinical study in colorectal cancer
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 5/1/2011 - 12/30/2014
 
Title: Colorectal Cancer Expansion Cohort Correlative Analysis
Funding Source: Plexxicon
Role: Principal Investigator
Duration: 3/1/2011 - 1/31/2014
 
Title: Evaluation of VEGF-C and VEGF-D in Patients with Metastatic Colorectal Cancer
Funding Source: Circadian Technologies Limited
Role: Principal Investigator
Duration: 2/1/2010 - 2/28/2013
 
Title: Investigator Initiated - Phase II study of second-line irinotecan plus brivanib, a dual tyrosine inhibitor of VEGFR and FGFR, in metastatic colorectal cancer patients enriched for elevated levels of plasma FGF following progression on bevacizumab-based treatment, Protocol
Funding Source: Bristol-Myers Squibb
Role: Co-Principal Investigator
Principal Investigator: Kopetz/Overman
Duration: 2010 - present
 
Title: Preclinical strategies for selection of patients with metastatic colon cancer susceptible to AZD0530 in combination with chemotherapy, Protocol
Funding Source: AstraZeneca
Role: Co-Principal Investigator
Principal Investigator: Gary Gallick
Duration: 9/1/2009 - 9/30/2013
 
Title: MicroRNAs and other non-coding RNAs in colorectal metastasis, R01, Protocol
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Calin/Hamilton/Kopetz
Duration: 6/8/2009 - 6/30/2011
 
Title: Src Inhibition in Colorectal Cancer, K23, Protocol
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2008 - 8/30/2013
 
Title: Career Development Award-Reversing Oxaliplatin Resistance with a Src Inhibitor in Colorectal Cancer, Protocol
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2008 - 6/30/2011
 
Title: Phase I study of two week TAS-109 (nucleoside analogue), Protocol
Funding Source: Taiho
Role: Principal Investigator
Duration: 7/6/2006 - 3/31/2008
 
Title: K12, Paul Calabresi Career Development Award for Clinical Oncology (Fellow: 2006-07, Faculty 2007-08), Protocol
Funding Source: NIH/NCI
Role: Investigator
Duration: 9/1/2005 - 8/30/2008

Last updated: 11/20/2014